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CASE SERIESA rare case of super giant basal cell carcinoma
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muscle tissue. Note the friable, rolled borders.
Abbreviation used:
BCC: basal cell carcinomaINTRODUCTION
Basal cell carcinoma (BCC) is the most common
skin cancer in the world, with 750,000 cases re-
ported annually in the United States alone.1,2
Because they are typically identified early, it is rare
to see BCCs grow beyond 5 cm in diameter; when
this does occur, the term giant basal cell carcinoma
applies. Furthermore, if beyond 20 cm in diameter,
the lesion is then termed super giant basal cell
carcinoma.3 Because of the rarity of such extensive
lesions, there is no consensus on treatment.
Although our patient ultimately did not receive
therapy for this lesion, similar cases have been
treated with surgery and radiation as the mainstays
of therapy. However, recent development and use
of vismodegib has provided a less-invasive alterna-
tive to consider. This case report illustrates a case of
a super giant BCC that developed in a modern
western society secondary to neglect and poor
follow-up.Fig 2. Large islands of basaloid cells retracting from
surrounding skeletal muscle and stroma; indicating deeply
invasive BCC. (Hematoxylin-eosin stain.)CASE PRESENTATION
The patient is a 70-year-old well-educated,
accomplished artist and sculptor who presented
with intractable diarrhea and malaise. At the time
of examination, he had a large bath towel taped
to his back with an underlying necrotic lesion with
sharply demarcated, rolled borders measuring
20 3 25 cm (Fig 1). The wound, present for
more than 35 years, initially started as a ‘‘spider
bite’’ on his left upper shoulder in 1978, slowly
expanding until he sought medical attention in
1983.
At that time, his primary care doctor diagnosed the
lesion as BCC and excision was attempted. The
patient claimed the site never healed, and he was
lost to follow-up. Over the next decade, the site
continued to expand with frequent bleeding and
purulence. He did not seek medical attention for thern University, Silver Falls Dermatology.
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Fig 3. Illustration of the Hedgehog pathway under normal circumstances (no malignancy).
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in diameter. He sought a more holistic approach, as
he believed traditional medicine had failed him, and
saw a local chiropractor who began treating the
lesion with spinal manipulation and a blue light.
After months of poor results, the patient was referred
to a physician for evaluation. He was seen by a
dermatologist who biopsied the lesion and made the
diagnosis of BCC (Fig 2), but the patient declined
further interventions, as he felt he was treated poorly
by the practice.
Over the next 20 years, the lesion continued to
grow, and the only treatment he received was blue
light therapy and spinal manipulation from his
chiropractor. In July of 2013, he fell ill with headache,
diarrhea, and lethargy, and the super giant BCC was
rediscovered. At this time, the wound edges were
biopsied, showing an infiltrative BCC with skeletal
muscle invasion. A computed tomography scan
found a mass in the liver consistent with probable
metastasis. The patient refused liver biopsy; there-
fore, metastasis was assumed but never proven.
Because the patient was a poor surgical candidate
and lesion was too large for complete excision, the
oncology department recommended the patient be
treated with vismodegib. Unfortunately, the patient
died from complications of cancer before the medi-
cation was started.
DISCUSSION
Although typically an indolent, slow-growing
cancer, BCC can become aggressive and locallyinvasive if left untreated. Giant BCC only accounts
for 0.5% of BCCs and super giant BCC is exceedingly
rare.4 Literature review found only 9 previously
reported cases.4,5 These lesions are most commonly
found on areas covered by clothing and typically
expand because of ongoing neglect by the patient.6
Archontaki et al7 published a review of 51 cases of
giant BCCs ([5 cm) with the risk of metastases
estimated around 6%. The review also documented a
significant increase in mortality in patients with
metastases.
Previously, treatment options for giant BCC were
limited to surgical excision, radiation therapy, and
chemotherapy. Vismodegib, a hedgehog pathway
inhibitor, acts directly on the G proteinecoupled
Smoothened receptor. This unique therapy was
approved by the US Food and Drug Administration
in 2012 for locally advanced and metastatic BCC.2
With the Smoothened receptor inhibited, neither
downstream signaling to the protein Sufu nor release
of Gli proteins can occur. This leads to decreased
Gli1 and Gli2, which are strong activators of tran-
scription of basal cells. Furthermore, because Sufu is
not activated, degradation of the transcription-
inhibiting Gli3 protein does not occur and allows
Gli3 to function at a baseline inhibitory level (Fig 3)8.
Of note, the beneficial biological properties of
vismodegib occur regardless of PTCH1 input.
Response rates were measured at 30% and 43% for
metastatic and locally advanced BCC, respectively.
Median duration of treatment was 7.6 months.9
Although response rates remain low, one must
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tumor reduction or clearance for those who might
otherwise have no options for treatment.CONCLUSION
Giant BCCs greater than 20 cm in diameter are
exceedingly rare; we report the tenth case found in
the literature. Treatment is often difficult; metastatic
rates and mortality dramatically increase with these
large lesions. A relatively new therapy, vismodegib,
has proven to be an option for some patients in
whom treatment may not have previously been
available or beneficial for metastatic and locally
aggressive BCC.REFERENCES
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